Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Pulmonary Arterial Hypertension (PAH) Therapeutics – Global Drug ForecastsAfter Strong Growth in 2002-2011, Patent Expiries or Loss of Orphan Drug Exclusivities Expected to Cause Negative Growth in Market
By: Rajesh Gunnam The global PAH therapeutics market is estimated to be worth $3.1 billion in 2020. It is forecast to show a negative CAGR of 0.6% during 2011 to 2020. This trend is on the account of significant number of patent expiries or loss of ODE in the forecast period. The majority of the marketed drugs (Tracleer, Letairis, Remodulin, Ventavis, Revatio and Adcirca) will lose either their patent protection or ODE during 2011 to 2020. Several pipeline drugs such as macitentan, selexipag, riociguat and imatinib, are also expected to enter the market in forecast period. Imatinib, riociguat and selexipag are First-In-Class (FIC) while macitentan is a me-too with enhanced safety and efficacy. However, the loss of patent protection or ODE will have a strong impact and will result in negative growth. In 2020, the three leading drugs in the major PAH therapeutics market will be riociguat, macitentan and Tyvaso with estimated sales of $700.5m, $437.7m and $421.3m, respectively. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ The current competition in the global PAH therapeutics market is strong in spite of low patient numbers; this is due to the high competitive intensity in the PAH therapeutics market. There are three main classes of drugs present in the market: Endothelin Receptor Antagonist (ERA), prostacyclins, and Phosphodiesterase- Industry analysis specialist GlobalData has released its new report, “Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020”, an essential and comprehensive source of information and analysis on the global Pulmonary Arterial Hypertension (PAH) therapeutics market. The report identifies and analyzes the key trends shaping and driving the global PAH therapeutics market, as well as treatment usage patterns in the global PAH therapeutics market. The competitive landscape is also covered, with insights into the emerging players expected to significantly alter the positions of the existing market leaders. An in-depth analysis of current pipeline products offers up valuable insights, and the report quantifies the unmet need in the global PAH therapeutics market as well as in the markets of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China, India and Russia, highlighting opportunities for future players. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
|